Brind.

Eli Lilly and Novo Nordisk are pivoting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.

Steady: 0 in the last 7 days Updated oct 8

The latest in this situation

  1. Studies involving Eli Lilly and Novo Nordisk report reductions in biological age using aging-clock methods.
  2. Eli Lilly and Novo Nordisk are pivoting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.

How it started

1 report, 1 independent, last reported Sep 16. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Eli Lilly and Novo Nordisk are pivoting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.

Who's involved

What this event is mainly about
Eli Lilly and CompanyNovo Nordisk

How it developed

Newest first. Tap a step to see who reported it.
  1. Studies involving Eli Lilly and Novo Nordisk report reductions in biological age using aging-clock methods.Sub-event
  2. Drug companies are framing their products as longevity therapeutics and investing in related biotech.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped